Device Good Manufacturing Practice Advisory Committee; Notice of Meeting, 9066 [2022-03476]
Download as PDF
9066
Federal Register / Vol. 87, No. 33 / Thursday, February 17, 2022 / Notices
Dated: February 14, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–03430 Filed 2–16–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–N–0008]
Device Good Manufacturing Practice
Advisory Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency)
announces a forthcoming public
advisory committee meeting of the
Device Good Manufacturing Practice
Advisory Committee. The committee
reviews regulations proposed for
promulgation regarding good
manufacturing practices governing the
methods used in, and the facilities and
controls used for, the manufacture,
packing, storage, and installation of
devices, and makes recommendations to
the Commissioner of Food and Drugs
regarding the feasibility and
reasonableness of those proposed
regulations. The meeting will be open to
the public.
DATES: The meeting will take place
virtually on March 2, 2022, from 9 a.m.
to 6 p.m. Eastern Time.
ADDRESSES: Please note that due to the
impact of this COVID–19 pandemic, all
meeting participants will be joining this
advisory committee meeting via an
online teleconferencing platform.
Answers to commonly asked questions
including information regarding special
accommodations due to a disability may
be accessed at: https://www.fda.gov/
advisory-committees/about-advisorycommittees/common-questions-andanswers-about-fda-advisory-committeemeetings.
SUMMARY:
lotter on DSK11XQN23PROD with NOTICES1
FOR FURTHER INFORMATION CONTACT:
Jarrod Collier, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5214, Silver Spring,
MD 20993–0002, Jarrod.Collier@
fda.hhs.gov, 240–672–5763, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last-minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
VerDate Sep<11>2014
17:23 Feb 16, 2022
Jkt 256001
enough to provide timely notice.
Therefore, you should always check the
Agency’s website at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before the meeting. The
meeting will be webcast and will be
available at the following links:
YouTube (primary): https://youtu.be/
SPrNfVb2Yv8 and TEAMS (captions):
https://teams.microsoft.com/. Please log
on 20 minutes before the webcast to test
your signal. You may have to refresh
your browser before logging on.
SUPPLEMENTARY INFORMATION:
Agenda: The meeting presentations
will be heard, viewed, captioned, and
recorded through an online
teleconferencing platform. As required
by section 520(f)(1)(B) of the Federal
Food, Drug, and Cosmetic Act (FD&C
Act) (21 U.S.C. 360j(f)(1)(B)), on March
2, 2022, the committee will discuss and
make recommendations on the current
good manufacturing practice
requirements for medical devices under
21 CFR part 820, the Quality System
Regulation, to align more closely with
an international consensus standard for
medical devices used by other
regulatory authorities.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its website prior to the
meeting, the background material will
be made publicly available on FDA’s
website at the time of the advisory
committee meeting, and the background
material will be posted on FDA’s
website after the meeting. Background
material and the link to the online
teleconference meeting room will be
available at https://www.fda.gov/
advisory-committees/medical-devices/
device-good-manufacturing-practiceadvisory-committee. Select the link for
the 2022 Meeting Materials. The
meeting will include slide presentations
with audio components to allow the
presentation of materials in a manner
that most closely resembles an in-person
advisory committee meeting.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before February 24, 2022.
Oral presentations from the public will
be scheduled on March 2, 2022,
between approximately 1:30 p.m. to
2:30 p.m. Eastern Time. Those
individuals interested in making formal
PO 00000
Frm 00040
Fmt 4703
Sfmt 9990
oral presentations should notify the
contact person (see FOR FURTHER
INFORMATION CONTACT). The notification
should include a brief statement of the
general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before February
21, 2022. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by February 22, 2022.
For press inquiries, please contact the
Office of Media Affairs at fdaoma@
fda.hhs.gov or 301–796–4540.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact AnnMarie
Williams at AnnMarie.Williams@
fda.hhs.gov or 301–796–5966 at least 7
days in advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our website at
https://www.fda.gov/advisorycommittees/about-advisory-committees/
public-conduct-during-fda-advisorycommittee-meetings for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: February 10, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–03476 Filed 2–16–22; 8:45 am]
BILLING CODE 4164–01–P
E:\FR\FM\17FEN1.SGM
17FEN1
Agencies
[Federal Register Volume 87, Number 33 (Thursday, February 17, 2022)]
[Notices]
[Page 9066]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-03476]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2021-N-0008]
Device Good Manufacturing Practice Advisory Committee; Notice of
Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) announces a
forthcoming public advisory committee meeting of the Device Good
Manufacturing Practice Advisory Committee. The committee reviews
regulations proposed for promulgation regarding good manufacturing
practices governing the methods used in, and the facilities and
controls used for, the manufacture, packing, storage, and installation
of devices, and makes recommendations to the Commissioner of Food and
Drugs regarding the feasibility and reasonableness of those proposed
regulations. The meeting will be open to the public.
DATES: The meeting will take place virtually on March 2, 2022, from 9
a.m. to 6 p.m. Eastern Time.
ADDRESSES: Please note that due to the impact of this COVID-19
pandemic, all meeting participants will be joining this advisory
committee meeting via an online teleconferencing platform. Answers to
commonly asked questions including information regarding special
accommodations due to a disability may be accessed at: https://www.fda.gov/advisory-committees/about-advisory-committees/common-questions-and-answers-about-fda-advisory-committee-meetings.
FOR FURTHER INFORMATION CONTACT: Jarrod Collier, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5214, Silver Spring, MD 20993-0002,
[email protected], 240-672-5763, or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area). A notice in the Federal Register about last-minute modifications
that impact a previously announced advisory committee meeting cannot
always be published quickly enough to provide timely notice. Therefore,
you should always check the Agency's website at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate
advisory committee meeting link, or call the advisory committee
information line to learn about possible modifications before the
meeting. The meeting will be webcast and will be available at the
following links: YouTube (primary): https://youtu.be/SPrNfVb2Yv8 and
TEAMS (captions): https://teams.microsoft.com/. Please log on 20
minutes before the webcast to test your signal. You may have to refresh
your browser before logging on.
SUPPLEMENTARY INFORMATION:
Agenda: The meeting presentations will be heard, viewed, captioned,
and recorded through an online teleconferencing platform. As required
by section 520(f)(1)(B) of the Federal Food, Drug, and Cosmetic Act
(FD&C Act) (21 U.S.C. 360j(f)(1)(B)), on March 2, 2022, the committee
will discuss and make recommendations on the current good manufacturing
practice requirements for medical devices under 21 CFR part 820, the
Quality System Regulation, to align more closely with an international
consensus standard for medical devices used by other regulatory
authorities.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its website prior to the meeting, the
background material will be made publicly available on FDA's website at
the time of the advisory committee meeting, and the background material
will be posted on FDA's website after the meeting. Background material
and the link to the online teleconference meeting room will be
available at https://www.fda.gov/advisory-committees/medical-devices/device-good-manufacturing-practice-advisory-committee. Select the link
for the 2022 Meeting Materials. The meeting will include slide
presentations with audio components to allow the presentation of
materials in a manner that most closely resembles an in-person advisory
committee meeting.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
February 24, 2022. Oral presentations from the public will be scheduled
on March 2, 2022, between approximately 1:30 p.m. to 2:30 p.m. Eastern
Time. Those individuals interested in making formal oral presentations
should notify the contact person (see FOR FURTHER INFORMATION CONTACT).
The notification should include a brief statement of the general nature
of the evidence or arguments they wish to present, the names and
addresses of proposed participants, and an indication of the
approximate time requested to make their presentation on or before
February 21, 2022. Time allotted for each presentation may be limited.
If the number of registrants requesting to speak is greater than can be
reasonably accommodated during the scheduled open public hearing
session, FDA may conduct a lottery to determine the speakers for the
scheduled open public hearing session. The contact person will notify
interested persons regarding their request to speak by February 22,
2022.
For press inquiries, please contact the Office of Media Affairs at
[email protected] or 301-796-4540.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact AnnMarie Williams at [email protected] or 301-796-
5966 at least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our website at https://www.fda.gov/advisory-committees/about-advisory-committees/public-conduct-during-fda-advisory-committee-meetings for procedures on public conduct during
advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: February 10, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-03476 Filed 2-16-22; 8:45 am]
BILLING CODE 4164-01-P